Extract

The purpose of this study is to compare the efficacy, safety, pharmacokinetics, and immunogenicity in subjects retreated with visilizumab or placebo after a response in a prior visilizumab study.

Inclusion criteria

• Ulcerative colitis

Country

• Australia
• Austria
• Belgium
• Canada
• Croatia
• Czech Republic
• France
• Germany
• Hungary
• Israel
• Italy
• Netherlands
• Norway
• Ukraine
• United States

Links

• nct
• ictrp